Vaxcyte (PCVX) Stock Price, News & Analysis

Company Overview

Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes. These candidates are being developed for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. The company is also advancing additional vaccine programs targeting other bacterial pathogens, although its pipeline remains focused primarily on pneumococcal disease.

Founded in 2013 as SutroVax and renamed Vaxcyte in 2020, the company is headquartered in San Carlos, California. Vaxcyte is developing its vaccine candidates for potential use in global markets and does not currently have a marketed commercial product. Grant Pickering, Ph.D., serves as the company’s chief executive officer.

Key Stats

• Today's Range: $55.84 to $57.00
• 50-Day Range: $52.98 to $63.30
• 52-Week Range: $39.87 to $65.00
• Volume: 2.40 million shs
• Average Volume: 1.39 million shs
• Market Capitalization: $8.40 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $104.40
• Consensus Rating: Moderate Buy

Vaxcyte Stock Analysis - MarketRank™

Vaxcyte scored higher than 43% of companies evaluated by MarketBeat, and ranked 511th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vaxcyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Vaxcyte has a consensus price target of $104.40, representing about 85.3% upside from its current price of $56.35.

Amount of Analyst Coverage

Vaxcyte has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vaxcyte are expected to grow in the coming year, from ($7.60) to ($6.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxcyte is -7.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxcyte is -7.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vaxcyte has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.21% of the float of Vaxcyte has been sold short.

Short Interest Ratio / Days to Cover

Vaxcyte has a short interest ratio ("days to cover") of 13.04, which indicates bearish sentiment.

Change versus previous month

Short interest in Vaxcyte has recently increased by 7.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxcyte does not currently pay a dividend.

Dividend Growth

Vaxcyte does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.33

News Sentiment

Vaxcyte has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Vaxcyte this week, compared to 4 articles on an average week.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,556,482.00 in company stock.

Percentage Held by Insiders

3.30% of the stock of Vaxcyte is held by insiders.

Percentage Held by Institutions

96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PCVX
• CIK: 1649094
• Web: www.vaxcyte.com
• Phone: 650-837-0111
• Fax: N/A
• Employees: 507
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Vaxcyte: $104.40
• High Price Target: $130.00
• Low Price Target: $77.00
• Potential Upside/Downside: +84.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$766.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -37.56%
• Return on Assets: -33.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.72
• Quick Ratio: 5.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $20.51 per share
• Price / Book: 2.75

Miscellaneous

• Outstanding Shares: 148,800,000
• Free Float: 143,894,000
• Market Cap: $8.40 billion
• Optionable: Optionable
• Beta: 1.23